BCBo-Wen Chen

Bo-Wen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bo-Wen Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Hailong Tao

    Department of Cardiology, the First affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

    2 shared publications
  • He-Ping Gu

    Department of Cardiology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China

    2 shared publications
  • Jun-Hui Xing

    Department of Cardiology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China

    2 shared publications
  • Heng-Dao Liu

    The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, China

    1 shared publication
  • Hengdao Liu

    Department of Cardiology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China

    1 shared publication
  • Jia-Jing Liu

    The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, China

    1 shared publication

Latest Publications

  • Open Access

    Safety and Efficacy of Drug-Coated Balloons in Patients with Acute Coronary Syndromes and Vulnerable Plaque

    by Yu-Bin Zhang, Heng-Dao Liu, Jun-Hui Xing, Bo-Wen Chen, Yan-Yan Zhao, He-Ping Gu, Hai-Long Tao

    Background: Percutaneous coronary intervention (PCI) is the main treatment option for acute coronary syndromes (ACS) often related to the progression and rupture of vulnerable plaques. While drug-eluting stents (DES) are now routinely used in PCI, drug-coated balloons (DCB) are a new strategy to PCI and their practice in the treatment of ACS with vulnerable plaques has not been reported. This study aimed to evaluate the safety and efficacy of DCB in ACS complicated with vulnerable plaque lesions. Methods: 123 patients were retrospectively analyzed and diagnosed with ACS and given PCI in our Cardiology Department from December 2020 to July 2022. Vulnerable plaques were confirmed by intravenous ultrasound (IVUS) in all patients. According to individual treatment plan, patients were entered into either DCB (n = 55) or DES (n = 68) groups. The results of coronary angiography and IVUS before and immediately after percutaneous coronary intervention were analyzed. The occurrence of major adverse cardiovascular events (MACE) and the results of coronary angiography were also evaluated during follow-up. Results: There were no significant differences in baseline clinical characteristics, preoperative minimal luminal diameter (MLD), and preoperative diameter stenosis (DS) between the two groups. Also, there were no differences in IVUS plaque burden (PB), vessel area, and lumen area in the two groups before and immediately after PCI. The efficacy analysis showed that immediately after PCI, the DCB group had smaller MLD and higher degrees of lumen stenosis than the DES group ( P < 0.05). However, during follow-up, no significant differences in MLD and DS were seen in two groups; relatively, late loss in luminal diameter(LLL)in the DCB group was smaller ( P<0.05). Safety analysis showed that during follow-up, 9 patients developed restenosis after DCB implantation while restenosis occurred in 10 patients with DES treatment, no statistical difference in the incidence of restenosis in the two groups. Besides, there was no statistical difference in the incidence of major adverse cardiac events(MACE)during hospitalization and follow-up in the DCB group (7.3% (4/55)) and the DES group (8.8% (6/68)). Conclusion: DCB is safe and effective for ACS complicated with vulnerable plaque and has an advantage over DES in LLL.


  • Open Access

    Analysis of the Correlation Between the Ratio of Monocytes to High-Density Lipoprotein Cholesterol and in-Stent Restenosis in Patients with Premature Coronary Heart Disease

    by Bo-Wen Chen, Jia-Jing Liu, Jun-Hui Xing, Heng-Dao Liu, Yu-Zhen Wei, Xiao-Fei Xue, He-Ping Gu, Hai-Long Tao

    Background: High-density lipoprotein cholesterol (HDL-C) and monocytes are associated with coronary artery disease, and the ratio of monocytes to high-density lipoprotein (MHR) is associated with long-term adverse outcomes and the recurrence of atrial fibrillation. Currently, the trend of coronary heart disease proned to young people is becoming prominent. However, the relationship between MHR and in-stent restenosis (ISR) in patients with premature coronary heart disease (PCHD) has not been investigated. Therefore, we aimed to assess the relationship between MHR and ISR in patients with PCHD. Methods: We retrospectively included 257 patients (men ≤ 55 years old, women ≤ 65 years old) with PCHD who underwent drug-eluting stent implantation and follow-up coronary angiography at the First Affiliated Hospital of Zhengzhou University from September 2016 to September 2019. Patients were divided into ISR and non-ISR groups depending on their follow-up coronary angiography results. Relative clinical information was recorded and analyzed. A receiver operating characteristic curve analysis was used to determine the optimum pre-procedural MHR cutoff value to predict ISR. Results: Logistic regression analysis showed that MHR, smoking history, and fibrinogen were independent risk factors for ISR in patients with PCHD. The area under the receiver operating characteristic curve (AUC) of MHR was 0.750 (95% confidence interval, 0.695-0.820; P < .001), the cutoff value was 546.88, and the specificity and sensitivity were 65.2% and 78%, while the AUC of monocytes was 0.631 (95% confidence interval, 0.638-0.794; P < .001), the cutoff value was 590, and the specificity and sensitivity were 77.1% and 60.0%. Conclusion: MHR is an independent risk factor for ISR in patients with PCHD and showed a certain predictive value.